Demographic and clinical characteristics of HCT survivors and siblings
| Characteristic . | Survivors (N = 1022), n (%) . | Siblings (N = 309), n (%) . | P . |
|---|---|---|---|
| Male sex, n (%) | 559 (54.7) | 113 (36.6) | < .001 |
| Race, n (%)* | .004 | ||
| Non-Hispanic white | 825 (80.7) | 270 (88.0) | |
| Others | 197 (19.3) | 37 (12.0) | |
| Education, n (%)* | .001 | ||
| Less than high school completion | 65 (6.4) | 5 (1.6) | |
| High school/some college or training | 492 (48.3) | 130 (42.2) | |
| College graduate/postgraduate | 461 (45.3) | 173 (56.2) | |
| Household income per year, n (%)* | < .001 | ||
| More than $60 000 | 438 (45.8) | 189 (64.3) | |
| $20 000-$60 000 | 383 (40.1) | 93 (31.6) | |
| Less than $20 000 | 135 (14.1) | 12 (4.1) | |
| With health insurance, n (%)* | 934 (92.6) | 291 (95.4) | .08 |
| Age at study participation, y | .03 | ||
| Mean ± SD | 43.1 ± 12.0 | 44.8 ± 11.8 | |
| Range | 18-73 | 19-79 | |
| Age at HCT, y | |||
| Mean ± SD | 34.4 ± 14.1 | NA | |
| Range | 0.4-69 | NA | |
| Interval between HCT and study, y | |||
| Mean ± SD | 8.6 ± 5.3 | NA | |
| Range | 2-28 | NA | |
| Primary cancer diagnosis, n (%) | |||
| Aplastic anemia | 53 (5.2) | NA | |
| CML | 236 (23.1) | NA | |
| AML | 244 (23.9) | NA | |
| Hodgkin lymphoma | 92 (9.0) | NA | |
| NHL | 203 (19.9) | NA | |
| ALL | 100 (9.8) | NA | |
| Multiple myeloma | 42 (4.1) | NA | |
| Others | 52 (5.1) | NA | |
| Stem cell donor, n (%) | |||
| Autologous HCT | 458 (44.8) | NA | |
| Allogeneic, sibling donor | 465 (45.5) | NA | |
| Allogeneic, unrelated donor | 99 (9.7) | NA | |
| Chronic GVHD, n (%) | |||
| Yes | 304 (29.8) | NA | |
| Risk of relapse at HCT, n (%)* | |||
| Standard risk | 662 (65.0) | NA | |
| High risk | 357 (35.0) | NA | |
| Preparative regimens, n (%) | |||
| Chemotherapy alone | 237 (23.3) | NA | |
| TBI-based | 782 (76.7) | NA | |
| TBI/cyclophosphamide | 404 (40.0) | NA | |
| TBI/cyclophosphamide/etoposide | 231 (22.7) | NA | |
| TBI/etoposide | 123 (12.1) | NA | |
| Any immunosuppression, n (%) | 545 (53.4) | NA | |
| Methotrexate | 455 (44.6) | NA | |
| Cyclosporine | 372 (36.4) | NA | |
| Prednisone | 315 (30.9) | NA |
| Characteristic . | Survivors (N = 1022), n (%) . | Siblings (N = 309), n (%) . | P . |
|---|---|---|---|
| Male sex, n (%) | 559 (54.7) | 113 (36.6) | < .001 |
| Race, n (%)* | .004 | ||
| Non-Hispanic white | 825 (80.7) | 270 (88.0) | |
| Others | 197 (19.3) | 37 (12.0) | |
| Education, n (%)* | .001 | ||
| Less than high school completion | 65 (6.4) | 5 (1.6) | |
| High school/some college or training | 492 (48.3) | 130 (42.2) | |
| College graduate/postgraduate | 461 (45.3) | 173 (56.2) | |
| Household income per year, n (%)* | < .001 | ||
| More than $60 000 | 438 (45.8) | 189 (64.3) | |
| $20 000-$60 000 | 383 (40.1) | 93 (31.6) | |
| Less than $20 000 | 135 (14.1) | 12 (4.1) | |
| With health insurance, n (%)* | 934 (92.6) | 291 (95.4) | .08 |
| Age at study participation, y | .03 | ||
| Mean ± SD | 43.1 ± 12.0 | 44.8 ± 11.8 | |
| Range | 18-73 | 19-79 | |
| Age at HCT, y | |||
| Mean ± SD | 34.4 ± 14.1 | NA | |
| Range | 0.4-69 | NA | |
| Interval between HCT and study, y | |||
| Mean ± SD | 8.6 ± 5.3 | NA | |
| Range | 2-28 | NA | |
| Primary cancer diagnosis, n (%) | |||
| Aplastic anemia | 53 (5.2) | NA | |
| CML | 236 (23.1) | NA | |
| AML | 244 (23.9) | NA | |
| Hodgkin lymphoma | 92 (9.0) | NA | |
| NHL | 203 (19.9) | NA | |
| ALL | 100 (9.8) | NA | |
| Multiple myeloma | 42 (4.1) | NA | |
| Others | 52 (5.1) | NA | |
| Stem cell donor, n (%) | |||
| Autologous HCT | 458 (44.8) | NA | |
| Allogeneic, sibling donor | 465 (45.5) | NA | |
| Allogeneic, unrelated donor | 99 (9.7) | NA | |
| Chronic GVHD, n (%) | |||
| Yes | 304 (29.8) | NA | |
| Risk of relapse at HCT, n (%)* | |||
| Standard risk | 662 (65.0) | NA | |
| High risk | 357 (35.0) | NA | |
| Preparative regimens, n (%) | |||
| Chemotherapy alone | 237 (23.3) | NA | |
| TBI-based | 782 (76.7) | NA | |
| TBI/cyclophosphamide | 404 (40.0) | NA | |
| TBI/cyclophosphamide/etoposide | 231 (22.7) | NA | |
| TBI/etoposide | 123 (12.1) | NA | |
| Any immunosuppression, n (%) | 545 (53.4) | NA | |
| Methotrexate | 455 (44.6) | NA | |
| Cyclosporine | 372 (36.4) | NA | |
| Prednisone | 315 (30.9) | NA |
Percentages are based on the total number of participants who provided data for each variable, rather than on the total number of subjects in each cohort; percentages may not total 100 because of rounding.
NA indicates not applicable.
Two subjects with unknown race, 5 with unknown education, 90 with unknown income, 60 with unknown insurance information, and 3 with unknown risk of relapse were excluded.